Equities researchers at StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
The stock has a market capitalization of $6,000.00, a PE ratio of 0.00 and a beta of 1.61. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35. Genocea Biosciences has a 12-month low of $0.00 and a 12-month high of $0.00.
Genocea Biosciences Company Profile
Read More
- Five stocks we like better than Genocea Biosciences
- What Does a Stock Split Mean?
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Transportation Stocks Investing
- MarketBeat Week in Review – 11/4 – 11/8
- How to Effectively Use the MarketBeat Ratings Screener
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.